Tuberculosis and Respiratory Diseases

  • 제79권2호
  • /
  • Pages.85-90
  • /
  • 2016
  • /
  • 1738-3536(pISSN)
  • /
  • 2005-6184(eISSN)
대한결핵및호흡기학회 (The Korean Academy of Tuberculosis and Respiratory Diseases)
권호 표지
DOI QR코드

DOI QR Code

Identification of Alternative Splicing and Fusion Transcripts in Non-Small Cell Lung Cancer by RNA Sequencing

  • Hong, Yoonki (Department of Internal Medicine, Kangwon National University School of Medicine) ;
  • Kim, Woo Jin (Department of Internal Medicine, Kangwon National University School of Medicine) ;
  • Bang, Chi Young (Department of Internal Medicine, Kangwon National University School of Medicine) ;
  • Lee, Jae Cheol (Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Oh, Yeon-Mok (Department of Pulmonary and Critical Care Medicine and Clinical Research Center for Chronic Obstructive Airway Diseases, Asan Medical Center, University of Ulsan College of Medicine)
  • 투고 : 2015.07.18
  • 심사 : 2015.12.14
  • 발행 : 2016.03.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Background: Lung cancer is the most common cause of cancer related death. Alterations in gene sequence, structure, and expression have an important role in the pathogenesis of lung cancer. Fusion genes and alternative splicing of cancer-related genes have the potential to be oncogenic. In the current study, we performed RNA-sequencing (RNA-seq) to investigate potential fusion genes and alternative splicing in non-small cell lung cancer. Methods: RNA was isolated from lung tissues obtained from 86 subjects with lung cancer. The RNA samples from lung cancer and normal tissues were processed with RNA-seq using the HiSeq 2000 system. Fusion genes were evaluated using Defuse and ChimeraScan. Candidate fusion transcripts were validated by Sanger sequencing. Alternative splicing was analyzed using multivariate analysis of transcript sequencing and validated using quantitative real time polymerase chain reaction. Results: RNA-seq data identified oncogenic fusion genes EML4-ALK and SLC34A2-ROS1 in three of 86 normal-cancer paired samples. Nine distinct fusion transcripts were selected using DeFuse and ChimeraScan; of which, four fusion transcripts were validated by Sanger sequencing. In 33 squamous cell carcinoma, 29 tumor specific skipped exon events and six mutually exclusive exon events were identified. ITGB4 and PYCR1 were top genes that showed significant tumor specific splice variants. Conclusion: In conclusion, RNA-seq data identified novel potential fusion transcripts and splice variants. Further evaluation of their functional significance in the pathogenesis of lung cancer is required.

키워드

참고문헌

  1. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007;448:561-6. https://doi.org/10.1038/nature05945
  2. Seo JS, Ju YS, Lee WC, Shin JY, Lee JK, Bleazard T, et al. The transcriptional landscape and mutational profile of lung adenocarcinoma. Genome Res 2012;22:2109-19. https://doi.org/10.1101/gr.145144.112
  3. Kim SC, Jung Y, Park J, Cho S, Seo C, Kim J, et al. A high-dimensional, deep-sequencing study of lung adenocarcinoma in female never-smokers. PLoS One 2013;8:e55596. https://doi.org/10.1371/journal.pone.0055596
  4. Martin JA, Wang Z. Next-generation transcriptome assembly. Nat Rev Genet 2011;12:671-82. https://doi.org/10.1038/nrg3068
  5. Kim YJ, Kim HS. Alternative splicing and its impact as a cancer diagnostic marker. Genomics Inform 2012;10:74-80. https://doi.org/10.5808/GI.2012.10.2.74
  6. Black DL. Mechanisms of alternative pre-messenger RNA splicing. Annu Rev Biochem 2003;72:291-336. https://doi.org/10.1146/annurev.biochem.72.121801.161720
  7. Feng H, Qin Z, Zhang X. Opportunities and methods for studying alternative splicing in cancer with RNA-Seq. Cancer Lett 2013;340:179-91. https://doi.org/10.1016/j.canlet.2012.11.010
  8. Miura K, Fujibuchi W, Unno M. Splice isoforms as therapeutic targets for colorectal cancer. Carcinogenesis 2012;33:2311-9. https://doi.org/10.1093/carcin/bgs347
  9. McPherson A, Hormozdiari F, Zayed A, Giuliany R, Ha G, Sun MG, et al. deFuse: an algorithm for gene fusion discovery in tumor RNA-Seq data. PLoS Comput Biol 2011;7:e1001138. https://doi.org/10.1371/journal.pcbi.1001138
  10. Iyer MK, Chinnaiyan AM, Maher CA. ChimeraScan: a tool for identifying chimeric transcription in sequencing data. Bioinformatics 2011;27:2903-4. https://doi.org/10.1093/bioinformatics/btr467
  11. Trapnell C, Pachter L, Salzberg SL. TopHat: discovering splice junctions with RNA-Seq. Bioinformatics 2009;25:1105-11. https://doi.org/10.1093/bioinformatics/btp120
  12. Shen S, Park JW, Huang J, Dittmar KA, Lu ZX, Zhou Q, et al. MATS: a Bayesian framework for flexible detection of differential alternative splicing from RNA-Seq data. Nucleic Acids Res 2012;40:e61. https://doi.org/10.1093/nar/gkr1291
  13. Misquitta-Ali CM, Cheng E, O'Hanlon D, Liu N, McGlade CJ, Tsao MS, et al. Global profiling and molecular characterization of alternative splicing events misregulated in lung cancer. Mol Cell Biol 2011;31:138-50. https://doi.org/10.1128/MCB.00709-10
  14. Bando H, Atsumi T, Nishio T, Niwa H, Mishima S, Shimizu C, et al. Phosphorylation of the 6-phosphofructo-2-kinase/fructose 2,6-bisphosphatase/PFKFB3 family of glycolytic regulators in human cancer. Clin Cancer Res 2005;11:5784-92. https://doi.org/10.1158/1078-0432.CCR-05-0149
  15. Clem BF, O'Neal J, Tapolsky G, Clem AL, Imbert-Fernandez Y, Kerr DA 2nd, et al. Targeting 6-phosphofructo-2-kinase (PFKFB3) as a therapeutic strategy against cancer. Mol Cancer Ther 2013;12:1461-70. https://doi.org/10.1158/1535-7163.MCT-13-0097
  16. Dhanoa BS, Cogliati T, Satish AG, Bruford EA, Friedman JS. Update on the Kelch-like (KLHL ) gene family. Hum Genomics 2013;7:13. https://doi.org/10.1186/1479-7364-7-13
  17. Alsarraj J, Hunter KW. Bromodomain-containing protein 4: a dynamic regulator of breast cancer metastasis through modulation of the extracellular matrix. Int J Breast Cancer 2012;2012:670632.
  18. Golan-Gerstl R, Cohen M, Shilo A, Suh SS, Bakacs A, Coppola L, et al. Splicing factor hnRNP A2/B1 regulates tumor suppressor gene splicing and is an oncogenic driver in glioblastoma. Cancer Res 2011;71:4464-72. https://doi.org/10.1158/0008-5472.CAN-10-4410
  19. Shimamura S, Sasaki K, Tanaka M. The Src substrate SKAP2 regulates actin assembly by interacting with WAVE2 and cortactin proteins. J Biol Chem 2013;288:1171-83. https://doi.org/10.1074/jbc.M112.386722
  20. Banky B, Raso-Barnett L, Barbai T, Timar J, Becsagh P, Raso E. Characteristics of CD44 alternative splice pattern in the course of human colorectal adenocarcinoma progression. Mol Cancer 2012;11:83. https://doi.org/10.1186/1476-4598-11-83
  21. Zygalaki E, Tsaroucha EG, Kaklamanis L, Lianidou ES. Quantitative real-time reverse transcription PCR study of the expression of vascular endothelial growth factor (VEGF) splice variants and VEGF receptors (VEGFR-1 and VEGFR-2) in non small cell lung cancer. Clin Chem 2007;53:1433-9. https://doi.org/10.1373/clinchem.2007.086819
  22. Giancotti FG. Targeting integrin beta4 for cancer and antiangiogenic therapy. Trends Pharmacol Sci 2007;28:506-11. https://doi.org/10.1016/j.tips.2007.08.004
  23. Gardina PJ, Clark TA, Shimada B, Staples MK, Yang Q, Veitch J, et al. Alternative splicing and differential gene expression in colon cancer detected by a whole genome exon array. BMC Genomics 2006;7:325. https://doi.org/10.1186/1471-2164-7-325
  24. Jariwala U, Prescott J, Jia L, Barski A, Pregizer S, Cogan JP, et al. Identification of novel androgen receptor target genes in prostate cancer. Mol Cancer 2007;6:39. https://doi.org/10.1186/1476-4598-6-39

피인용 문헌

  1. Osteosarcoma enters a post genomic era with in silico opportunities: Generation of the High Dimensional Database for facilitating sarcoma biology research: A report from the Children's Oncology Grou vol.12, pp.7, 2016, https://doi.org/10.1371/journal.pone.0181204
  2. Identification of metabolism-associated genes and pathways involved in different stages of clear cell renal cell carcinoma vol.15, pp.2, 2016, https://doi.org/10.3892/ol.2017.7567
  3. Diagnosis and Treatment of Non-Squamous Lung Cancer Based on Molecular Tumor Testing vol.93, pp.3, 2016, https://doi.org/10.3904/kjm.2018.93.3.266
  4. Integrative molecular characterisation of gallbladder cancer reveals micro-environment-associated subtypes vol.74, pp.5, 2016, https://doi.org/10.1016/j.jhep.2020.11.033
  5. PYCR, a key enzyme in proline metabolism, functions in tumorigenesis vol.53, pp.12, 2016, https://doi.org/10.1007/s00726-021-03047-y